Status:
COMPLETED
Evaluation of Efficacy of Ophthalmic Solution in Induced Acute Allergic Conjunctivitis
Lead Sponsor:
Vistakon Pharmaceuticals
Conditions:
Allergic Conjunctivitis
Eligibility:
All Genders
10+ years
Phase:
PHASE3
Brief Summary
The purpose of this study is to establish the efficacy of R89674 0.25% ophthalmic solution compared with placebo in alleviating the signs and symptoms of conjunctival allergen challenge-induced allerg...
Eligibility Criteria
Inclusion
- history of ocular allergies and a positive skin test reaction to cat hair,
- cat dander, grasses, ragweed, and/or trees within the past 24 months;
- calculated best-corrected visual acuity of 0.6 logMar or better in each eye; - positive bilateral conjunctival allergy challenge reaction
Exclusion
- narrow angle glaucoma,
- clinically significant blepharitis, follicular conjunctivitis, iritis
- pterygium or diagnosis of dry eye
- ocular surgical intervention within 3 months
- history of refractive surgery within 6 months
- known history of retinal detachment, diabetic retinopathy, or progressive retinal disease
- presence of active ocular infection positive history of an ocular herpetic infection
- preauricular lymphadenopath manifest signs or symptoms of clinically active allergic conjunctivitis
Key Trial Info
Start Date :
October 1 2005
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT00241319
Start Date
October 1 2005
Last Update
September 27 2011
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Indianapolis, Indiana, United States
2
Lewiston, Maine, United States
3
Rochester, New York, United States
4
Charlotte, North Carolina, United States